Cargando…

Reactive Oxygen Species and Autophagy Modulation in Non-Marine Drugs and Marine Drugs

It is becoming more understandable that an existing challenge for translational research is the development of pharmaceuticals that appropriately target reactive oxygen species (ROS)-mediated molecular networks in cancer cells. In line with this approach, there is an overwhelmingly increasing list o...

Descripción completa

Detalles Bibliográficos
Autores principales: Farooqi, Ammad Ahmad, Fayyaz, Sundas, Hou, Ming-Feng, Li, Kun-Tzu, Tang, Jen-Yang, Chang, Hsueh-Wei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4245538/
https://www.ncbi.nlm.nih.gov/pubmed/25402829
http://dx.doi.org/10.3390/md12115408
Descripción
Sumario:It is becoming more understandable that an existing challenge for translational research is the development of pharmaceuticals that appropriately target reactive oxygen species (ROS)-mediated molecular networks in cancer cells. In line with this approach, there is an overwhelmingly increasing list of many non-marine drugs and marine drugs reported to be involved in inhibiting and suppressing cancer progression through ROS-mediated cell death. In this review, we describe the strategy of oxidative stress-based therapy and connect the ROS modulating effect to the regulation of apoptosis and autophagy. Finally, we focus on exploring the function and mechanism of cancer therapy by the autophagy modulators including inhibitors and inducers from non-marine drugs and marine drugs.